Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer

Kong,Fei-Fei; Qu,Zeng-Qiang; Yuan,Hai-Hua; Wang,Jiong-Yi; Zhao,Mei; Guo,Yue-Hui; Shi,Jing; Gong,Xiao-Di; Zhu,You-Long; Liu,Feng; Zhang,Wen-Ying; Jiang,Bin

doi:10.3892/or.2014.3129

Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer

Authors:
- Fei-Fei Kong
- Zeng-Qiang Qu
- Hai-Hua Yuan
- Jiong-Yi Wang
- Mei Zhao
- Yue-Hui Guo
- Jing Shi
- Xiao-Di Gong
- You-Long Zhu
- Feng Liu
- Wen-Ying Zhang
- Bin Jiang
View Affiliations

Affiliations: Department of Oncology, No. 3 People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine (SJTU-SM), Shanghai 201900, P.R. China, Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Department of General Surgery, No. 3 People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine (SJTU-SM), Shanghai 201900, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/or.2014.3129
Pages: 2660-2668

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Forkhead box M1 (FOXM1), a member of the Fox family of transcriptional factors, is considered to be an independent predictor of poor survival in many solid cancers. However, the underlying mechanism is not yet clear. The aim of the present study was to investigate the clinical significance of the correlation between FOXM1 and epithelial-mesenchymal transition (EMT) in non-small cell lung carcinoma and the possible mechanism responsible for FOXM1-induced EMT and metastasis. In the present study, expression levels of FOXM1 and EMT indicator proteins were determined by tissue microarray (TMA) and immunohistochemical staining, western blotting and reverse transcription-PCR (RT-PCR). Other cellular and molecular approaches including gene transfection, small interfering RNA (siRNA), and migration and invasion assays were utilized. Our results demonstrated that FOXM1 overexpression was statistically significantly associated with a higher TNM stage (p=0.036), lymph node metastasis (p=0.009) and a positive smoking history of the patients (p=0.044). Additionally, high expression of FOXM1 correlated with loss of E-cadherin expression (p<0.001) and anomalous immunopositivity of Vimentin (p=0.002). Moreover, patient survival analysis demonstrated that high expression of FOXM1 (p=0.043) and the presence of lymph node metastasis (p=0.042) were independent prognostic factors for non-small cell lung cancer (NSCLC). Furthermore, various in vitro experiments indicated that overexpression or knockdown of FOXM1 expression altered EMT through activation or inhibition of the AKT/p70S6K signaling pathway. Collectively, the results suggest that FOXM1 may be used as a prognostic indicator for patients with NSCLC and promotes metastasis by inducing EMT of lung cancer cells through activation of the AKT/p70S6K pathway. Therefore, we suggest that FOXM1 may be a potential target for lung cancer therapy.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung Cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
2	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
3	Laoukili J, Kooistra MR, Brás A, et al: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
4	Laoukili J, Stahl M and Medema RH: FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 1775:92–102. 2007.PubMed/NCBI
5	Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yang DK, Son CH, Lee SK, Choi PJ, Lee KE and Roh MS: Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol. 40:464–470. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sun HC, Li M, Lu JL, et al: Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep. 25:1533–1539. 2011.PubMed/NCBI
8	Bektas N, Haaf At, Veeck J, et al: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008. View Article : Google Scholar : PubMed/NCBI
9	Liu D, Zhang Z and Kong CZ: High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 34:1131–1138. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wu XR, Chen YH, Liu DM, Sha JJ, Xuan HQ, Bo JJ and Huang YR: Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol. 30:3462013. View Article : Google Scholar : PubMed/NCBI
11	He SY, Shen HW, Xu L, et al: FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol. 127:601–610. 2012. View Article : Google Scholar : PubMed/NCBI
12	Xu N, Jia D, Chen W, et al: FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One. 8:e594122013. View Article : Google Scholar : PubMed/NCBI
13	Chu XY, Zhu ZM, Chen LB, et al: FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem. 114:755–762. 2012. View Article : Google Scholar : PubMed/NCBI
14	Xue YJ, Xiao RH, Long DZ, et al: Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med. 10:2002012. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
16	Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ: Critical role of O-linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287:11070–11081. 2012.
17	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
18	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wu YD and Zhou BP: Snail: more than EMT. Cell Adh Migr. 4:199–203. 2010. View Article : Google Scholar
20	Christofori G: New signals from the invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
21	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
22	Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari HM and Goldman RD: Introducing intermediate filaments: from discovery to disease. J Clin Invest. 119:1763–1771. 2009. View Article : Google Scholar : PubMed/NCBI
23	Cheng GZ, Park S, Shu S, et al: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
24	Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H and Sato M: Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol. 29:1133–1138. 2006.PubMed/NCBI
25	Grille SJ, Bellacosa A, Upson J, et al: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63:2172–2178. 2003.
26	Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443–7454. 2005.
27	Schramek H, Feifel E, Marschitz I, Golochtchapova N, Gstraunthaler G and Montesano R: Loss of active MEK1-ERK1/2 restores epithelial phenotype and morphogenesis in transdifferentiated MDCK cells. Am J Physiol Cell Physiol. 285:C652–C661. 2003. View Article : Google Scholar : PubMed/NCBI
28	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
29	Park HJ, Gusarova G, Wang Z, et al: Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med. 3:21–34. 2011. View Article : Google Scholar : PubMed/NCBI
30	Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY and Jiang B: JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bao B, Wang Z, Ali S, Kong D, et al: Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem. 112:2296–2306. 2011. View Article : Google Scholar : PubMed/NCBI
32	Liu YQ, Guo RH, Liu LK, Gao W, Zhu CJ, Wei J and Shu YQ: Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi. 33:426–430. 2011.(In Chinese).
33	Li LP, Lu CH, Chen ZP, et al: Subcellular proteomics revealed the epithelial-mesenchymal transition phenotype in lung cancer. Proteomics. 11:429–439. 2011. View Article : Google Scholar : PubMed/NCBI
34	Wang G, Dong W, Shen H, Mu X, Li Z, Lin X, Liu Y and Du J: A comparison of Twist and E-cadherin protein expression in primary non-small-cell lung carcinoma and corresponding metastases. Eur J Cardiothorac Surg. 39:1028–1032. 2011. View Article : Google Scholar : PubMed/NCBI
35	Pirozzi G, Tirino V, Camerlingo R, et al: Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 6:e215482011.
36	Soltermann A, Tischler V, Arbogast S, et al: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
37	Zhao JQ, Sun FJ, Liu SS, et al: Expression of connexin 43 and E-cadherin protein and mRNA in non-small cell lung cancers in Chinese patients. Asian Pac J Cancer Prev. 14:639–643. 2013. View Article : Google Scholar : PubMed/NCBI
38	Zhang X, Wang Z, Kang Y, Li X, Ma X and Ma L: MCAM expression is associated with poor prognosis in non-small cell lung cancer. Clin Transl Oncol. 16:178–183. 2014. View Article : Google Scholar : PubMed/NCBI
39	Jin S, Zhu W, Shi Q, Zhang Z and Guo R: Clinicopathological significance of lymphatic vessel density marked by D2–40 and E-cadherin expression in non-small-cell lung cancer. Med Oncol. 29:3157–3161. 2012.
40	Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA and Yucel N: Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol. 47:397–402. 2011.(In Spanish).
41	Dauphin M, Barbe C, Lemaire S, et al: Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer. 81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
42	Irie HY, Pearline RV, Grueneberg D, et al: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034. 2005. View Article : Google Scholar : PubMed/NCBI